Department of Pathology, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.
Department of Meridians and Acupoints, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.
Medicine (Baltimore). 2022 Feb 18;101(7):e28892. doi: 10.1097/MD.0000000000028892.
Metabolic syndrome is a pathological condition characterized by abdominal obesity, insulin resistance, hypertension, and hyperlipidemia. Conventional treatments for metabolic syndrome have limitations due to their nonselectivity, drug resistance, and low bioavailability. The brown seaweed Laminaria japonica (LJP) is a traditional medicine and food in Asia that has shown pharmacological and biochemical properties favorable to the prevention and treatment of lifestyle-related diseases. We will systematically review randomized controlled trials and in vivo preclinical studies evaluating the efficacy and safety of LJP as a useful treatment for metabolic syndrome.
The following databases will be searched from inception to September 2021: MEDLINE (via PubMed), EMBASE, Cochrane Central Register of Controlled Trials, and Web of Science. Randomized controlled trials and in vivo preclinical studies that analyzed LJP for the prevention and treatment of metabolic syndromes will be included. The outcome measures will include body composition, dietary habit scores, serum lipid profiles, daily nutrient intake, quality of life, number of microbiomes, gastrointestinal symptoms, and bowel function. Studies comparing LJP with any type of control intervention will be included. Data extraction using Review Manager version 5.3 and risk of bias assessment using the Cochrane Collaboration's tool for assessing risk of bias will be performed by 2 independent assessors.
This systematic review will provide evidence confirming the efficacy and safety of LJP in the treatment of metabolic syndrome.
Ethical approval was not required, as this study protocol does not include any personal information of the participants.
DOI 10.17605/OSF.IO/G2BQK (https://osf.io/g2bqk).
代谢综合征是一种病理状态，其特征为腹部肥胖、胰岛素抵抗、高血压和血脂异常。由于非选择性、耐药性和低生物利用度，代谢综合征的常规治疗存在局限性。褐藻裙带菜（Laminaria japonica，LJP）是亚洲的传统药物和食品，具有有利于预防和治疗生活方式相关疾病的药理学和生化特性。我们将系统地综述评估 LJP 作为代谢综合征有效治疗方法的疗效和安全性的随机对照试验和体内临床前研究。
将从建库至 2021 年 9 月检索以下数据库：MEDLINE（通过 PubMed）、EMBASE、Cochrane 对照试验中心注册库和 Web of Science。将纳入分析 LJP 预防和治疗代谢综合征的随机对照试验和体内临床前研究。结局指标将包括身体成分、饮食习惯评分、血清脂质谱、每日营养素摄入、生活质量、微生物组数量、胃肠道症状和肠道功能。将纳入比较 LJP 与任何类型对照干预的研究。使用 Review Manager 版本 5.3 提取数据，并使用 Cochrane 协作风险偏倚评估工具评估 2 位独立评估者的风险偏倚。
本系统综述将提供证据，证实 LJP 治疗代谢综合征的疗效和安全性。
由于本研究方案不包含参与者的任何个人信息，因此不需要伦理批准。
DOI 10.17605/OSF.IO/G2BQK（https://osf.io/g2bqk）。
